Ensemble Orthopedics announced the 100th implantation of the Ensemble CMC™ minimally invasive joint replacement for the treatment of carpometacarpal (CMC or thumb) osteoarthritis, coinciding with the one-year anniversary of market introduction.
The FDA-cleared Ensemble CMC was designed to expand treatment options for CMC osteoarthritis in a wider range of patients by replacing only the affected bearing surfaces of the carpal and metacarpal bones. The interpositional device is inserted through a small incision with minimal disruption to the joint capsule or stabilizing soft tissue structures of the thumb. Ensemble CMC is manufactured from pyrocarbon, a low friction material with a proven history of durability and biocompatibility in orthopedic implants.
"The CMC implant is our initial offering in a complete line of minimally invasive implants for the hand and wrist," said William Ogilvie, Co-founder and CEO of Ensemble Orthopedics. "Our early experience suggests the implant presents an attractive choice for surgeons to offer patients and is becoming an accepted treatment alternative."
Source: Ensemble Orthopedics, Inc.